Abstract:Objective:To investigate whether spatial memory impairment occurred in mice with chronic neuropathic pain and to investigate transcriptome changes in their hippocampus.Methods:A total of 24 male C57BL/6 mice were divided into two groups according to the random number table method ( n=12): a Sham group and a chronic constrictive injury of sciatic nerve (CCI) group. The paw withdrawal mechanical threshold (PWMT) of each mouse was measured by Von Frey filament test before operation, and 7 days and 28 days after operation. The open-field test was used to detect motor ability and anxiety of the mice 7 days and 28 days after operation. The spatial memory of the mice was detected by the spatial position recognition test. Fresh hippocampal tissue was collected 28 days after operation for transcriptome sequencing to detect gene expression differences between the two groups. Real-time fluorescent quantitative polymerase chain reaction (RT-qPCR) was used to verify the gene expression of fibromodulin (FMOD), bone morphogenetic protein 7 (Bmp7), prostaglandin D2 synthase (PTGDS), and aldehyde dehydrogenase 1 family member A2 (Aldh1a2). Results:Compared with the Sham group, mice in the CCI group presented significantly decreased PWMT on the hind foot of the injured side 7 days ( t=6.01, P<0.001) and 28 days ( t=4.49, P<0.001) after operation. There were no significant differences in movement and anxiety between the two groups 7 and 28 days after surgery (movement distance: 7 days after surgery, t=0.25, P=0.962, and 28 days after surgery, t=0.32, P=0.939; time in center of the open field: 7 days after surgery, t=1.16, P=0.439, 28 days after surgery, t=0.34, P=0.931). There was no statistical difference in spatial memory between the two groups 7 days after surgery ( t=2.00, P=0.101), while the spatial memory of the CCI group was significantly lower than that of the Sham group 28 days after surgery ( t=2.93, P=0.011). Transcriptome sequencing results indicated the presence of a large number of differentially expressed genes (DEGs) in the hippocampus of the two groups. RT-qPCR showed that compared with that in the Sham group, the gene expression of FMOD ( t=8.07, P<0.001), Bmp7 ( t=4.81, P=0.003), PTGDS ( t=4.07, P=0.007) and Aldh1a2 ( t=7.93, P<0.001) in the hippocampus of mice in the CCI group decreased. Conclusions:Mice with chronic neuropathic pain may show spatial memory impairment, and the transcriptome of hippocampal tissue significantly changes.

Neuropeptide S Displays As a Key Neuromodulator in Olfactory Spatial Memory.

Neuropeptide S Ameliorates Olfactory Spatial Memory Impairment Induced by Scopolamine and MK801 Through Activation of Cognate Receptor-Expressing Neurons in the Subiculum Complex

Neuropeptide S Enhances Memory and Mitigates Memory Impairment Induced by MK801, Scopolamine or Aβ1–42 in Mice Novel Object and Object Location Recognition Tasks

Neuropeptide S facilitates spatial memory and mitigates spatial memory impairment induced by N-methyl-D-aspartate receptor antagonist in mice.

Neuropeptide S Facilitates Mice Olfactory Function Through Activation Of Cognate Receptor-Expressing Neurons In The Olfactory Cortex

Neuropeptide S Attenuates the Alarm Pheromone-Evoked Defensive and Risk Assessment Behaviors Through Activation of Cognate Receptor-Expressing Neurons in the Posterior Medial Amygdala

Neuropeptide S Interacts with the Basolateral Amygdala Noradrenergic System in Facilitating Object Recognition Memory Consolidation

Neuropeptide S promotes maintenance of newly formed dendritic spines and performance improvement after motor learning in mice

Neuropeptide S overcomes short term memory deficit induced by sleep restriction by increasing prefrontal cortex activity

The Ventromedial Hypothalamic Nucleus Plays an Important Role in Anxiolytic-Like Effect of Neuropeptide S

Spatial memory impairment and its transcriptomic profile in the hippocampus of chronic neuropathic pain mice

Neuropeptide S inhibits the acquisition and the expression of conditioned place preference to morphine in mice.

Dissociative Effects of Neuropeptide S Receptor Deficiency and Nasal Neuropeptide S Administration on T-Maze Discrimination and Reversal Learning

Central treatment of neuropeptide-S attenuates cognitive dysfunction and hippocampal synaptic plasticity impairment by increasing CaMKII/GluR1 in hemiparkinsonian rats

Neuropeptide S Encodes Stimulus Salience in the Paraventricular Thalamus

Neuropeptide S Produces Antinociceptive Effects at the Supraspinal Level in Mice

Central Neuropeptide S Inhibits Distal Colonic Transit Through Activation of Central Neuropeptide S Receptor in Mice

Neuropeptide S- and Neuropeptide S receptor-expressing neuron populations in the human pons

Mechanisms of neuropeptide Y2 receptor in improving the learning and memory of rats

Nociceptin and the NOP receptor in aversive learning in mice

Neuropeptide S Promotes Wakefulness Through Activation of the Posterior Hypothalamic Histaminergic and Orexinergic Neurons.